Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.64 |
| ▸ | ABL1 | P00519 | 7/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | RET | P07949 | 5/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.60 |
| ▸ | FYN | P06241 | 3/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | YES1 | P07947 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.60 |
| ▸ | PRKACA | P17612 | 2/20 | 0.60 |
| ▸ | FRK | P42685 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617301 | 0.79 | SRC (0.89) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL409031 | 0.79 | SRC (1.00) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL3781579 | 0.77 | PIK3CD (0.73) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL13019693 | 0.77 | SRC (0.68) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL3610160 | 0.76 | SRC (0.95) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL409444 | 0.76 | SRC (0.82) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL3611430 | 0.75 | SRC (0.72) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL407934 | 0.75 | SRC (1.00) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL29432587 | 0.75 | SRC (1.00) | SRCABL1PRKD3PRKD2KDR | |
| SCHEMBL409036 | 0.74 | SRC (0.80) | SRCABL1PRKD3PRKD2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482983-A4 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2006-07-12 | — | — | EP | claimed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| WO-2003065971-A9 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2003-11-20 | — | — | WO | claimed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | claimed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1482983-A4 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2006-07-12 | — | — | EP | disclosed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | disclosed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | disclosed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885ABL1 1725/4885PRKD3 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.